What is the 13F Pro Quality Score for CNSP?

13F Pro ranks CNS Pharmaceuticals, Inc. (CNSP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CNSP's current score at https://13fpro.ai/research/CNSP (free sign-up required for the full ranking).

Where does 13F Pro source CNSP data?

All CNS Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. CNS Pharmaceuticals, Inc. files with the SEC under CIK 1729427. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CNSP in?

CNS Pharmaceuticals, Inc. (CNSP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CNSP research updated on 13F Pro?

CNSP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CNS Pharmaceuticals, Inc.(CNSP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1729427 CNSP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CNSP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CNS Pharmaceuticals, Inc. (CNSP), a Healthcare sector company. CNSP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), CNS Pharmaceuticals, Inc. reports net income of $-4.9M, free cash flow of $-4.7M. Top institutional holders of CNSP by reported 13-F value include Stonepine Capital Management,, Ikarian Capital,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CNSP trades on the Nasdaq exchange and files with the SEC under CIK 1729427. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CNS Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-4.9M

Free Cash Flow

Q1 2026

$-4.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-6.7% YoY

$-15.9MFY 2025

FY21 $-14.5MFY23 $-18.9MFY24 $-14.9MFY25 $-15.9M

Operating Income

-7.3% YoY

$-16.0MFY 2025

FY21 $-14.5MFY23 $-18.9MFY24 $-14.9MFY25 $-16.0M

EPS (Diluted)

+92.3% YoY

$-35.75FY 2025

FY21 $-16.50FY23 $-12509.11FY24 $-466.89FY25 $-35.75

Total Assets

-0.9% YoY

$8.6MFY 2025

FY21 $8.8MFY23 $1.7MFY24 $8.7MFY25 $8.6M

Total Debt

—FY 2025

FY21 $426.0KFY23 —FY24 —FY25 —

Op. Cash Flow

+19.3% YoY

$-13.8MFY 2025

FY21 $-13.5MFY23 $-14.1MFY24 $-17.1MFY25 $-13.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Net Income	$-15.9M -6.7%	$-14.9M +21.2%	$-18.9M -30.1%	$-14.5M -53.3%	$-9.5M -143.9%	$-3.9M
Operating Income	$-16.0M -7.3%	$-14.9M +21.0%	$-18.9M -30.2%	$-14.5M -53.2%	$-9.5M -146.7%	$-3.8M
EPS (Diluted)	$-35.75 +92.3%	$-466.89 +96.3%	$-12509.11 -75712.8%	$-16.50	—	—
Total Assets	$8.6M -0.9%	$8.7M +411.6%	$1.7M -80.6%	$8.8M -44.8%	$15.9M +100.4%	$7.9M
Total Debt	—	—	—	$426.0K -11.7%	$482.4K	—
Operating Cash Flow	$-13.8M +19.3%	$-17.1M -21.0%	$-14.1M -4.4%	$-13.5M -85.0%	$-7.3M -105.9%	$-3.6M

AI Insight: CNSP Financial Trends

CNS Pharmaceuticals remains pre-revenue with cumulative net losses of $32M over eight quarters and equity eroding to zero by Q1 2026.

• Net losses ranged $2–6M per quarter; Q1 2026 posted $5M loss with operating cash burn of $5M, sustaining negative FCF throughout.

• Equity swung from $-4M (Q2 2024) to peak of $13M (Q2 2025), then collapsed to $0M by Q1 2026—no revenue to offset burn.

⚠ Equity erosion to zero signals imminent need for dilutive financing or asset sales to continue operations.

⚠ No revenue reported across all eight quarters; clinical-stage company burning $2–7M quarterly with no near-term commercialization visible.

AI Insight: CNSP Ratio Trends

Insufficient operating and profitability data to establish meaningful trends; only fragmented ROE/ROA/ROIC metrics available, all deeply negative in mid-2025.

• ROE collapsed to -156.8% in Q1 2025, then moderated to -72.4% in Q2 2025, suggesting loss-driven equity deterioration.

• Q2 2025 ROA and ROIC both at -65.5% and -73.4% respectively, reflecting severe negative profitability.

⚠ ROE rebounded to -129.9% in Q3 2025; direction and magnitude of losses remain opaque without operating metrics.

⚠ No margin, leverage, or operating data available; inability to assess operational efficiency or balance-sheet health.

Get alerted when CNSP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CNS Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CNSP

Stonepine Capital Management, LLC
$145.8K61,000 sh
Ikarian Capital, LLC
$110.0K45,830 sh
GEODE CAPITAL MANAGEMENT, LLC
$55.7K23,189 sh
BOOTHBAY FUND MANAGEMENT, LLC
$32.3K13,524 sh
Tower Research Capital LLC (TRC)
$3.1K1,310 sh
UBS Group AG
$1.7K729 sh
Sound Income Strategies, LLC
$36.0016 sh
BARRETT & COMPANY, INC.
$19.008 sh
MAI Capital Management
$8.003 sh
CITIGROUP INC
$2.001 sh

Fund	Value	Shares
Stonepine Capital Management, LLC	$145.8K	61,000
Ikarian Capital, LLC	$110.0K	45,830
GEODE CAPITAL MANAGEMENT, LLC	$55.7K	23,189
BOOTHBAY FUND MANAGEMENT, LLC	$32.3K	13,524
Tower Research Capital LLC (TRC)	$3.1K	1,310
UBS Group AG	$1.7K	729
Sound Income Strategies, LLC	$36.00	16
BARRETT & COMPANY, INC.	$19.00	8
MAI Capital Management	$8.00	3
CITIGROUP INC	$2.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CNSP on your watchlist

Track score changes the day CNS Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CNSP a good stock to buy?

13F Pro's AI-powered analysis of CNS Pharmaceuticals, Inc. (CNSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNSP are available on the CNSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CNSP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CNS Pharmaceuticals, Inc.'s investment landscape.